chrisvoncsefalvay/vaers-outcomes huggingface dataset:
No additional adverse events reported; On 04-DEC-2021, the patient received VARIVAX and On 23-DEC-2021, the patient received MMR/Interruption in schedule; This spontaneous report was received from a nurse referring to herself as a female patient of unknown age. The patient's medical history, historical drugs, concurrent conditions and concomitant medications were not provided.     On 08-NOV-2021, the patient received the first dose of varicella virus vaccine live (Oka/Merck). On 04-DEC-2021, the patient received the second dose of varicella virus vaccine live (Oka/Merck) (VARIVAX). On 23-DEC-2021, the patient received the first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II). On 21-JAN-2022, the patient received the second dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (doses, routes of administration, lot numbers and expiration dates were not reported for any dose). Both vaccines were given as prophylaxis.  The nurse reported that her records were flagged with a interruption in the schedule (Inappropriate schedule of product administration). No additional adverse events reported.
Roaring headache, vomiting and diarrhea.  Duration 2 hours.
Severe ataxia; muscle weakness; dizziness; headaches; hand tremors; leg and arm pain; brain fog; numbness; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 03Nov2021 08:30 (Batch/Lot number: unknown) at the age of 47 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Sulfa based medication allergy" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: ATAXIA (hospitalization, disability) with onset 05Nov2021, outcome "not recovered", described as "Severe ataxia"; MUSCULAR WEAKNESS (hospitalization, disability) with onset 05Nov2021, outcome "not recovered", described as "muscle weakness"; DIZZINESS (hospitalization, disability) with onset 05Nov2021, outcome "not recovered", described as "dizziness"; HEADACHE (hospitalization, disability) with onset 05Nov2021, outcome "not recovered", described as "headaches"; TREMOR (hospitalization, disability) with onset 05Nov2021, outcome "not recovered", described as "hand tremors"; PAIN IN EXTREMITY (hospitalization, disability) with onset 05Nov2021, outcome "not recovered", described as "leg and arm pain"; FEELING ABNORMAL (hospitalization, disability) with onset 05Nov2021, outcome "not recovered", described as "brain fog"; HYPOAESTHESIA (hospitalization, disability) with onset 05Nov2021, outcome "not recovered", described as "numbness". The patient was hospitalized for ataxia, muscular weakness, dizziness, headache, tremor, pain in extremity, feeling abnormal, hypoaesthesia (hospitalization duration: 1 day(s)). The events "severe ataxia", "muscle weakness", "dizziness", "headaches", "hand tremors", "leg and arm pain", "brain fog" and "numbness" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (09Nov2021) negative; (16Nov2021) negative. Therapeutic measures were taken as a result of ataxia, muscular weakness, dizziness, headache, tremor, pain in extremity, feeling abnormal, hypoaesthesia which included Muscle relaxers, physical therapy. Clinical course: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pt had a hypersensitivity reaction to her COVID 19 vaccine. Her symptoms included becoming flush and tachycardic.  Her BP was elevated initially (209/117).  She did endorse forgetting to take her BP medications this AM and failing to eat anything for breakfast.  A medical response was called and the patient received 10 mg of Zyrtec po.  An EKG was obtained and read as normal by the responding provider.  The patient was observed for a period of 90 minutes until her symptoms resolved and her BP and HR improved. She also had a snack and drink.
Rash 11/24/2009 TSH 0.006, recheck 12/01/2009 TSH 0.006 T4 & T3 WNL, Referral to clinic 12/07/2009 TSH 0.01 T4 1.41 & T3 160, Subsequently developed tachycardia, arrhythmias, air hunger, weight loss etc 01/05/2010 TSH less than 0.01 T4 2.8 T3 247. Placed in INDERAL 10 mg TID for tachycardia and 10 mg METHIMAZOLE BID for thyroid suppression.
Shingles; Poison ivy; wrists (palm side up) broke out/ Rash/ Itchy rash; Hurts; Single lumps on my arms and near my nose and upper lip; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 59-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 11th April 2019, the patient received the 1st dose of Shingrix. On 14th April 2019, 3 days after receiving Shingrix, the patient experienced shingles, poison ivy rash, itchy rash and pain. In April 2019, the patient experienced mass. On an unknown date, the outcome of the shingles, poison ivy rash, itchy rash, pain and mass were not reported.   It was unknown if the reporter considered the shingles, poison ivy rash, itchy rash, pain and mass to be related to Shingrix.  Additional details were provided as follows: This case was reported by the patient. The reporter stated that she had a rash and did not know if it was shingles or poison ivy. The patient was out in some brush on Wednesday. The patient received the first Shingrix shot on Thursday. The patient's wrists (palm side up) broke out on Sunday, right wrist was worse than left. The rash was not really itchy as much as it was hurting. The patient was periodically noticing single lumps on arms and near nose and upper lip in less than a week after receiving vaccine. If needed, the permission to contact the patient's physician was granted.
COVID-19  Body aches  Runny nose  Diarrhea, unspecified type  Cough  Close exposure to COVID-19 virus  Fever, unspecified fever cause
booster; She tested positive for covid and experiencing very mild stuffy nose and sore throat; She tested positive for covid and experiencing very mild stuffy nose and sore throat; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 16 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 3 (booster), single, (Batch/Lot number: unknown) as dose 2, single and (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: IMMUNISATION (medically significant), outcome "unknown", described as "booster"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "She tested positive for covid and experiencing very mild stuffy nose and sore throat". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: positive.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Nasuea and night sweats a day or two after 1st dose - no longer occuring. At injection site - rash, welt, hives - raised, hard, silver dollar sized. round, itchy, painful.  Still occuring -- > getting redder and redder, heat coming off of it.
I26.99 PULMONARY EMBOLISM, UNSPECIFIED. 1/24/2022 HYPOTHYROIDISM I82.403 ACUTE DVT OF BILAT LEGS, UNSPECIFIED VEINS 1/31/2022 HYPOTHYROIDISM I95.9 HYPOTENSION 1/24/2022 HYPOTHYROIDISM J96.00 ACUTE RESPIRATORY FAILURE 3/8/2022 HYPOTHYROIDISM R57.0 CARDIOGENIC SHOCK 1/24/2022 HYPOTHYROIDISM
she did not have the sound in her ears/Having bug sounds in ears; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 02Mar2021 (Lot number: EL9263, Expiration Date: May2021) at the age of 70 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "diagnosed allergies" (unspecified if ongoing); "compromised immune status" (unspecified if ongoing); "respiratory illness" (unspecified if ongoing); "genetic /chromosomal abnormalities" (unspecified if ongoing); "endocrine abnormalities" (unspecified if ongoing), notes: including diabetes; "Obesity" (unspecified if ongoing); "Allergic to Peanuts diagnosed 2005", start date: 2005 (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: TINNITUS (non-serious) with onset Mar2021, outcome "not recovered", described as "she did not have the sound in her ears/Having bug sounds in ears". The event "she did not have the sound in her ears/having bug sounds in ears" was evaluated at the physician office visit. Therapeutic measures were taken as a result of tinnitus.  Additional information: Reporter reported that she having bug sounds in ear approximately 2 weeks ago, unknown time of day. She saw her doctor last week, Examined and diagnosed with Tinnitus and said it could be not for sure. She prescribed Amoxicillin 875 mg tablet. One tablet twice daily for 7 days. It is in a pharmacy vial with no lot or expiration. Dr said that this was an allergic reaction and people are reporting hearing sounds in their ears. She does not have any specific information on those people to report. Her Height was provided as 5'4" or 5'5. She never had any soreness in either arm. No prior vaccinations (within 4 weeks) and no AE following prior vaccinations. Family medical history was none. Patient never had any soreness in either arm. She was unable to confirm if either were injected in the muscle, because she did not feel either one.  No follow-up attempts are possible. No further information is expected.
3 days after the 1st Shingrix vaccination the patient develop a rash and hives on both arms and body as they described it. She has she has been treated with oral and topical steriods and oral hydroxazine. Condition is still going on  to the current date of this submission.
Had normal swelling and soreness at injection site for a couple of days. Last night noticed my arm in the area of the injection was hot, swollen and itchy.    Had also had surgery (bilateral breast reconstruction) on 11/15.  Did not have lymph nodes removed on that side during my double Mastectomy that was August 12.
PATIENT REPORTED SWELLING AND PAIN IN HER ARM DOWN TO THE MIDDLE OF HER FOREARM. NO REDNESS.
Information has been received from a physician from the Pregnancy Registry for GARDASIL concerning a female who was vaccinated with GARDASIL.  The patient became pregnant and went into labor.  On an unknown date, the patient experienced loss of amniotic fluid and had to undergo surgery.  No information is available on the outcome of both, mother and child.  Loss of amniotic fluid was considered to be immediately life-threatening.  No further information is available.
Pt recvd Hep B vax in JUL91 & exp burning & pain @ inject site; lot number of Hep B vax was changed & sx did not recur;
Pt states tingling in hand, difficulty holding object and soreness at injection site and site of injection.
Covid-19 symptoms: cough beginning on 7/13/22 (Day 0). Fairly intense runny nose, sneezing, fatigue, body aches, lack of motivation from about 7/14/22-7/17/22 (Days 1-4). Symptoms began lessening on 7/18/22 (Day 5). Gradual improvement through Day 10 (July 23,2022). As I fill out this form on 7/26/2022 (Day 13) I still have some nasal congestion and a little cough (infrequent). Only treatment was rest, keeping hydrated, taking Excedrin Extra-Strength occasionally.
Information has been reported in a CDC slide titled as "Safety of PNEUMOVAX 23 in the Vaccine Adverse Reporting System (VAERS)". This spontaneous prospective pregnancy report as received from a registered nurse (RN) in Centers for Disease Control and Prevention (CDC) concerning a female patient of unknown age, 3 of the four patients who experienced no adverse event. On an unknown date, the patient became pregnant. The last menstrual period (LMP) and estimated date of delivery (EDD) was not known. On an unknown date the patient was administered with a dose of PNEUMOVAX 23 (lot#, dose and route were unspecified) during pregnancy. No adverse event reported. The outcome of pregnancy was unknown. The pregnancy outcome was unknown. This is one of the 18 reports (PNEUMOVAX 23 administered during pregnancy) that received from the same source. Additional information has been requested.
Mosquito bite rash above waist on right; Rash at injection site; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Mosquito bite rash above waist on right) and INJECTION SITE RASH (Rash at injection site) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, the patient experienced RASH (Mosquito bite rash above waist on right) and INJECTION SITE RASH (Rash at injection site). At the time of the report, RASH (Mosquito bite rash above waist on right) and INJECTION SITE RASH (Rash at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment and concomitant medications were not provided by reporter.
Vertigo, Anxiety,Tinnitus,Frequent Headaches Inflammation muscular and skeletal.
Fever; body pain; under the left arm at injection site it got red and warm; under the left arm at injection site it got red and warm; This is a spontaneous report from a contactable consumer (patient). A 33-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, lot number: Ew0170) via an unspecified route of administration, administered in arm left on 28Apr2021 (age at vaccination was 33-year-old) as a dose number unknown, single for covid-19 immunisation. The patient's medical history included known allergies: lactose. The patient's concomitant medications were not reported. No other vaccine in four weeks. No covid prior vaccination. The patient experienced fever and body pain, on second day under the left arm at injection site it got red and warm on 30Apr2021. She did not receive treatments for adverse events. No covid tested post vaccination. The outcome of events was recovering.   Follow up activities were closed. No follow up attempt was made.
Low estrogen; can't concentrate; can't focus; can't sleep; depressed; has anxiety; This is a spontaneous report received from contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient and reporting similar event(s) under the same suspect product(s) for 10 patients. This consumer reported for an unknown patient that:  A patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: BLOOD OESTROGEN DECREASED (non-serious), outcome "unknown", described as "Low estrogen"; DISTURBANCE IN ATTENTION (non-serious), outcome "unknown", described as "can't concentrate"; VISION BLURRED (non-serious), outcome "unknown", described as "can't focus"; INSOMNIA (non-serious), outcome "unknown", described as "can't sleep"; DEPRESSED MOOD (non-serious), outcome "unknown", described as "depressed"; ANXIETY (non-serious), outcome "unknown", described as "has anxiety". Relevant laboratory tests and procedures are available in the appropriate section.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER_INC-202101533632 same drug and AE, different patient.
I couldn?t lift my arm after 11pm it was very sore and my left side was slouching the whole night. It hurt even when I wasn?t moving it it was just throbbing and pulsating. If I need to lift my arm I had to use my right arm just to maneuver my left.  It stopped after 5 days and each day it got a little better. Then the following week it was hurting again when I moved it certain ways for a total of a week.
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 59-year-old female patient who received SHINGRIX. The patient's past medical history included lymphoma. Concomitant products included valsartan and IMBRUVICA. In January 2018, the patient received the 1st dose of SHINGRIX .5 ml. On an unknown date, 1 day after receiving SHINGRIX, the patient experienced injection site pain, injection site erythema, injection site swelling and injection site warmth. On an unknown date, the outcome of the injection site pain, injection site erythema, injection site swelling and injection site warmth were recovered/resolved. The reporter considered the injection site pain, injection site erythema and injection site swelling to be related to SHINGRIX. It was unknown if the reporter considered the injection site warmth to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. This case was previously reported to a physician. The patient received SHINGRIX on left arm in her oncologist's office. The reporter reported that 24 hours after injection she developed pain, redness and swelling at the injection site that she categorized as severe. The reporter reported that on day two it was warm to the touch and that all events were resolved after about 3 to 4 days. The reporter was unable to provide full demographics of oncologist.
pt recvd vax 31JAN95 & had fever of 104 31JAN95 noc; pt seen in ER 1FEB95 w/t105 & hives throughout body; dx allergic react & treated w/DPH; released from ER 1FEB95;
I got extremely tired. I would put my head down and would fall asleep. It took a full day after getting the vaccine to feel this way. It lasted all through the weekend. I started feeling headaches. Then I started to have abdominal problems. I was having really severe diarrhea. That lasted for about a day. It was like I had a little flu episode there. I went in to see my doctor yesterday. I think that maybe I got the booster too soon after my 2nd dose. I had more of a reaction this time. My immune system feels like it is in overdrive.
patient broke out in hives, she was given Benadryl and later given an EpiPen and  left with the  ems
Employee stated that she felt symptoms of increased heart rate, swollen throat, difficulty breathing while she was still at work approximately 2000. Employee went home and developed hives around 2100. Employee took some Benadryl and went to sleep. She awoke the following day and all her symptoms had resolved. Employee did not seek medical attention. Employee did not report symptoms to medical staff until 10/23/2019.
Patient presented to Adult Clinic on 11/20/2017 c/o redness, pain, itchiness, and swelling to right deltoid at injection site for PCV 13. Patient denies SOB, throat swelling, and/difficulty breathing. Patient states symptoms are getting better from initial vaccine administration day. Advised pt to continue to monitor, place ice pack to area 10-20 mins every 2-3 hours as needed, can use OTC Benadryl cream for itchiness. Will notify MD. Patient will continue to monitor and return to clinic if has any new or worsening symptoms.
Pt was seen at PCP office for Annual Wellness Visit. He could not recall if he had received his COVID Bivalent Vaccine. Pfizer COVID Bivalent vaccine was administered on 11/3/22.  Staff member entered the vaccine into registry to discover the patient did in fact already receive his Pfizer COVID Bivalent Vaccine on 9/20/2022 at a local pharmacy, so it was not documented in our electronic medical record.
After receiving vaccine, patient stood up from chair and started to feel "dizzy." Patient was assisted back to chair by staff. Upon assessment, patient was pale to face and warm to touch. BP 102/58, P88. SpO2 99% on room air. Given gatorade water to drink and cool compresses applied to neck. Extended monitoring done in recovery. Patient ambulated from facility with mother. No s/sx of distress noted.
Difficulty breathing; Dizziness; High blood pressure; Fast heart beat; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), HYPERTENSION (High blood pressure), HEART RATE INCREASED (Fast heart beat) and DYSPNOEA (Difficulty breathing) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced DIZZINESS (Dizziness), HYPERTENSION (High blood pressure) and HEART RATE INCREASED (Fast heart beat). On 12-Mar-2021, the patient experienced DYSPNOEA (Difficulty breathing). The patient was treated with METOPROLOL at an unspecified dose and frequency. At the time of the report, DIZZINESS (Dizziness), HYPERTENSION (High blood pressure) and HEART RATE INCREASED (Fast heart beat) outcome was unknown and DYSPNOEA (Difficulty breathing) had not resolved. Unknown      mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Concomitant product use was not provided by the reporter.  patient was using nebulizer for treatment.
Patient was given Pfizer vaccine for 3rd dose even though he had Moderna for 1st and 2nd dosages. Patient waited for 30minutes and had no adverse reactions at time of injection. Patient was given Pfizer vaccine for 3rd dose even though he had Moderna for 1st and 2nd dosages.
Bells Palsy; This is a spontaneous report from a contactable consumer (patient).   A 53-years-old patient of an unspecified gender received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 1 via an unspecified route of administration, administered in Arm Left in Mar2021 (Lot Number: EN6205; expiration date unknown), age at vaccination of  53-years-old, as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported.  On 23Mar2021, the patient experienced tingling on right side, drooping on right side, unable to blink right eye, bells palsy was diagnosed. Events resulted in Emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included administration of antibiotics. Facility type Vaccine: Public Health Clinic/Veterans; no other vaccine in four weeks, no other medications in two weeks; no Covid prior vaccination and patient was not Covid tested post vaccination. The patient had not recovered from the events.
This spontaneous report as received from a physician via a company representative refers to a female patient of unknown age. On an unknown date the patient was vaccinated with ZOSTAVAX for prophylaxis. Concomitant therapies included sterile diluent. On an unknown date, "10 days" after vaccination, the patient experienced "unconfirmed shingles rash on her neck". The patient sought medical attention and was treated. The outcome of herpes zoster was unknown.